バイラルベクター及びプラスミドDNA製造の世界市場: ベクター別(レンチウイルス、レトロウイルス)、ワークフロー別、用途別、エンドユーザー別、疾患別

【英語タイトル】Viral Vectors & Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Vector (Lentivirus, Retrovirus), By Workflow, By Application, By End Use, By Disease, And Segment Forecasts, 2020 - 2027

Grand View Researchが出版した調査資料(GVR20MA125)・商品コード:GVR20MA125
・発行会社(調査会社):Grand View Research
・発行日:2020年2月28日
・ページ数:250
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥642,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥750,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥966,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、バイラルベクター及びプラスミドDNA製造の世界市場について調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場の要因・動向・範囲、ベクター別(レンチウイルス、レトロウイルス、プラスミドDNA、AAV、レンチウイルス)分析、ワークフロー別(アップストリーム製造、ダウンストリーム製造)分析、用途別(アンチセンス&RNAi療法、細胞療法、遺伝子療法、ワクチン)分析、エンドユーザー別(製薬およびバイオ製薬会社、研究機関)分析、疾患別(がん、遺伝性疾患、感染症、その他)分析、地域別分析、競争状況などの構成でお届けいたします。
・調査手法
・エグゼクティブサマリー
・市場の要因・動向・範囲
・バイラルベクター及びプラスミドDNA製造の世界市場:ベクター別(レンチウイルス、レトロウイルス、プラスミドDNA、AAV、レンチウイルス)
・バイラルベクター及びプラスミドDNA製造の世界市場:ワークフロー別(アップストリーム製造、ダウンストリーム製造)
・バイラルベクター及びプラスミドDNA製造の世界市場:用途別(アンチセンス&RNAi療法、細胞療法、遺伝子療法、ワクチン)
・バイラルベクター及びプラスミドDNA製造の世界市場:エンドユーザー別(製薬およびバイオ製薬会社、研究機関)
・バイラルベクター及びプラスミドDNA製造の世界市場:疾患別(がん、遺伝性疾患、感染症、その他)
・バイラルベクター及びプラスミドDNA製造の世界市場:地域別
・競争状況
【レポートの概要】

The global viral vectors & plasmid DNA manufacturing market size is expected to reach USD 1.1 billion by 2027, exhibiting a 14.52% CAGR, during the forecast period, according to a new report by Grand View Research, Inc. Currently, more than 700 cell and gene therapies are in clinical trials and vectors are used in nearly 70% of these therapies. As a result, demand for vectors has exceeded the supply rate. Thus, an increase in the number of advanced therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive investments in the market.

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.

Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market. For example, the introduction of ready-to-run factory-in-a-box to accelerate the production of virus-based therapeutics by GE healthcare, as a solution to simplify and advance the manufacturing process.

Further key findings from the report suggest:

• With high usage, attributed to its ability of high titer production and capability to induce strong humoral and T cell responses in various research applications, adenovirus held the leading viral vectors and plasmid DNA manufacturing market share in terms of revenue, in 2019

• Lentivirus vector is anticipated to register the fastest CAGR over the forecast period. This can be attributed to constant growth in the lentivirus-based gene therapy pipeline program

• Downstream processing held the dominant revenue share in 2019, owing to the fact that this process involves purification steps that account for the majority of the overall manufacturing cost. Employment of expensive equipment and requirement of trained personnel for product recovery has further driven revenue in the segment

• Antisense and RNAi therapy production is estimated as the key application of vector manufacturing, resulting in the dominance of this segment over other applications

• The high adoption rate of viruses for aptamers and oligonucleotide development in comparison to other applications has driven revenue in antisense and RNAi therapy segment

• High usage of vectors for therapeutic production have contributed to the large revenue share of pharmaceutical and biopharmaceutical companies. The number of biotech companies employing vector for therapies production is anticipated to multiply over the forecast period

• Presence of a substantial number of advanced therapy products in the pipeline targeting various cancer forms has accelerated revenue share of the cancer segment over the years

• Given the high number of biotech entities in parts of U.S., such as in California and Massachusetts, North America has maintained its dominance in terms of revenue. In addition, the active participation of regulatory bodies in improving the regulatory scenario for the market launch of advanced therapies has facilitated the high usage of vectors in U.S.

• Merck, Cobra Biologics, Novasep, and uniQure N.V., are some key participants that are geared towards capitalizing the untapped opportunities in the market

【レポートの目次】

Table of content

Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2 Technological advancements in manufacturing vectors
3.1.1.3 Highly competitive market and various strategies undertaken by market entities
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity challenges
3.1.3.1 Manufacturing challenges pertaining to large-scale production of vectors
3.1.4 Opportunity analysis
3.1.4.1 Facility expansion for cell and gene therapies
3.2 Viral Vector Production: Stepwise Challenges & Solutions
3.2.1 Plasmid Production: Challenges & Solutions
3.2.2 Host Cell Production & Banking Needs
3.2.3 Viral Vector Production, F&F: Challenges & Solutions
3.2.4 Viral Vector Production, Analytics: Challenges & Solutions
3.3 Penetration & Growth Prospect Mapping for Vector Type, 2019
3.4 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.5 Manufacturer’s Landscape
3.6 Viral Vector & Plasmid DNA Manufacturing Market-SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.7 Industry Analysis – Porter’s
Chapter 4 Viral Vector Production Capacity Mapping Analysis
4.1 CMOs Capacity for Viral Vector Manufacturing
4.2 In-house Manufacturers Capacity for Viral Vector Manufacturing
4.3 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers
4.4 Prominent Players: Location Mapping & existing Capacities
4.5 AAV and LV vector candidate developing organizations
4.6 CMO Mammalian Cell Culture Capacity of Key Players in Viral Vector/Gene/Cell Therapy Space: Key Statistics
4.7 Mammalian cell lines: Capacity & Investments
4.7.1 Small Scale Companies: Mammalian Cell Culture Capacities
4.7.2 Medium scale companies: Mammalian cell culture capacities
4.7.3 Large scale companies: Mammalian cell culture capacities
4.8 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
4.9 List of Vector Manufacturers
Chapter 5 Viral Vector Production: Costs
5.1 Cost Models
5.1.1 Campaign model
5.1.2 Day rate model
5.1.3 Hybrid model
Chapter 6 Viral Vector Production & Yield Analysis
6.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
6.2 Various Modes of Vector Production to increase & achieve Target Doses
6.2.1 Adenoviral vectors
6.2.2 γ- retroviral (MLV – murineleukemia virus) vectors
6.2.3 Lentiviral vectors
6.2.4 AAV vectors
6.2.5 rAAV vectors
6.2.5.1 rAAV Production : Challenges & Solutions
6.3 Total vector quantity produced per day and yield volume using different cell culture systems
6.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
6.5 Analysis of large- and small-scale production of viral vectors based on batch size
6.5.1 Small-scale/laboratory-scale cell culture systems
6.5.2 Large-scale cell culture systems
6.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing
Chapter 7 Viral Vector Manufacturing: Process Economic Considerations & Challenges
7.1 Technological Advances in Manufacturing
7.1.1 Stable Producer Cell Lines
7.1.2 Transient production
7.1.3 Lentiviral vector production process
7.1.3.1 Developments in LentiVector platform
7.2 CoGs Analysis of the Baseline Process
7.2.1 Raw Material
7.2.2 Labor costs
7.2.3 Process costs
7.3 Regulatory Expectations
7.4 Approaches for Viral Vector Supply Gene Therapy
7.4.1 Gene Therapy Manufacturing Facilities: Trends & Types
7.4.2 Gene Therapy Road Map: Key External Trends
Chapter 8 Viral Vector Manufacturing Market: Strategic Alliances
8.1 Is The Time Right To Invest In Gene Therapy Sector?
8.2 Strategic Approaches for Market Scale-Up
8.3 Partnership Models
8.3.1 Acquisition
8.3.2 Minority interest (ownership)
8.3.3 Joint venture
8.3.4 Alliance
8.3.5 Franchise
8.4 Collaborations in Viral Vector Manufacturing Market
8.4.1 Breakthrough Growth: Lonza, Oxford BioMedica & Others
Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
9.2 Adenovirus
9.2.1 Global adenovirus market, 2016 – 2027 (USD Million)
9.3 Retrovirus
9.3.1 Global retrovirus market, 2016 – 2027 (USD Million)
9.4 Plasmid DNA
9.4.1 Global plasmid DNA market, 2016 – 2027 (USD Million)
9.5 AAV
9.5.1 Global AAV market, 2016 – 2027 (USD Million)
9.6 Lentivirus
9.6.1 Global lentivirus market, 2016 – 2027 (USD Million)
9.7 Other Vectors
9.7.1 Global other vectors market, 2016 – 2027 (USD Million)
Chapter 10 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
10.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
10.2 Upstream Manufacturing
10.2.1 Global upstream manufacturing market, 2016 – 2027 (USD Million)
10.2.2 Vector amplification & expansion
10.2.2.1 Global vector amplification & expansion market, 2016 – 2027 (USD Million)
10.2.3 Vector recovery/harvesting
10.2.3.1 Global vector recovery/harvesting market, 2016 – 2027 (USD Million)
10.3 Downstream Manufacturing
10.3.1 Global downstream manufacturing market, 2016 – 2027 (USD Million)
10.3.2 Purification
10.3.2.1 Global purification market, 2016 – 2027 (USD Million)
10.3.3 Fill Finish
10.3.3.1 Global fill finish market, 2016 – 2027 (USD Million)
Chapter 11 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
11.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
11.2 Antisense & RNAi Therapy
11.2.1 Market for antisense, & RNAi therapy, 2016 – 2027 (USD Million)
11.3 Cell Therapy
11.3.1 Market for cell therapy, 2016 – 2027 (USD Million)
11.4 Gene Therapy
11.4.1 Market for gene therapy, 2016 – 2027 (USD Million)
11.5 Vaccinology
11.5.1 Market for vaccinology, 2016 – 2027 (USD Million)
Chapter 12 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
12.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
12.2 Pharmaceutical and Biopharmaceutical Companies
12.2.1 Market for pharmaceutical and biopharmaceutical companies, 2016 – 2027 (USD Million)
12.3 Research Institutes
12.3.1 Market for research institutes, 2016 – 2027 (USD Million)
Chapter 13 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
13.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
13.2 Cancer
13.2.1 Market for cancer, 2016 – 2027 (USD Million)
13.3 Genetic Disorders
13.3.1 Market for genetic disorders, 2016 – 2027 (USD Million)
13.4 Infectious Diseases
13.4.1 Market for infectious diseases, 2016 – 2027 (USD Million)
13.5 Others
13.5.1 Market for other diseases, 2016 – 2027 (USD Million)
Chapter 14 Market Categorization: Regional Estimates & Trend Analysis, by Product
14.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2019 & 2027
14.2 North America
14.2.1 North America viral vector & plasmid DNA manufacturing market, 2016 – 2027 (USD Million)
14.2.2 U.S.
14.2.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.2.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.2.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.2.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.2.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.2.3 Canada
14.2.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.2.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.2.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.2.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.2.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.3 Europe
14.3.1 Europe viral vector & plasmid DNA manufacturing market, 2016 – 2027 (USD Million)
14.3.2 Germany
14.3.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.3.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.3.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.3.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.3.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.3.3 U.K.
14.3.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.3.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.3.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.3.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.3.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.4 Asia Pacific
14.4.1 Asia Pacific viral vector & plasmid DNA manufacturing market, 2016 – 2027 (USD Million)
14.4.2 Japan
14.4.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.4.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.4.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.4.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.4.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.4.3 China
14.4.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.4.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.4.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.4.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.4.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.5 Latin America
14.5.1 Latin America viral vector & plasmid DNA manufacturing market, 2016 – 2027 (USD Million)
14.5.2 Brazil
14.5.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.5.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.5.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.5.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.5.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
14.6 MEA
14.6.1 MEA viral vector & plasmid DNA manufacturing market, 2016 – 2027 (USD Million)
14.6.2 South Africa
14.6.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 – 2027 (USD Million)
14.6.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 – 2027 (USD Million)
14.6.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 – 2027 (USD Million)
14.6.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 – 2027 (USD Million)
14.6.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 – 2027 (USD Million)
Chapter 15 Competitive Landscape
15.1 Strategy Framework
15.2 Market Participation Categorization
15.3 Company Profiles: Contract Manufacturing Organizations (CMOs)
15.3.1 Merck KGaA
15.3.1.1 Company overview
15.3.1.1.1 Sigma-Aldrich Co. LLC
15.3.1.2 Financial performance
15.3.1.3 Product benchmarking
15.3.1.4 SWOT analysis
15.3.1.5 Operational capacity
15.3.1.6 Strategic initiatives
15.3.2 Lonza
15.3.2.1 Company overview
15.3.2.2 Financial performance
15.3.2.3 Product benchmarking
15.3.2.4 SWOT analysis
15.3.2.5 Operational capacity
15.3.2.6 Strategic initiatives
15.3.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.3.3.1 Company overview
15.3.3.2 Financial performance
15.3.3.3 Product benchmarking
15.3.3.4 SWOT analysis
15.3.3.5 Operational capacity
15.3.3.6 Strategic initiatives
15.3.4 Cobra Biologics Ltd.
15.3.4.1 Company overview
15.3.4.2 Financial performance
15.3.4.3 Product benchmarking
15.3.4.4 SWOT analysis
15.3.4.5 Operational capacity
15.3.4.6 Strategic initiatives
15.3.5 Brammer Bio
15.3.5.1 Company overview
15.3.5.2 Financial performance
15.3.5.3 Product benchmarking
15.3.5.4 SWOT analysis
15.3.5.5 Operational capacity
15.3.5.6 Strategic initiatives
15.3.6 Waisman Biomanufacturing
15.3.6.1 Company overview
15.3.6.2 Financial performance
15.3.6.3 Product benchmarking
15.3.6.4 SWOT analysis
15.3.6.5 Operational capacity
15.3.6.6 Strategic initiatives
15.3.7 Genezen
15.3.7.1 Company overview
15.3.7.2 Product benchmarking
15.3.7.3 SWOT analysis
15.3.7.4 Operational capacity
15.3.7.5 Strategic initiatives
15.3.8 YPOSKESI
15.3.8.1 Company overview
15.3.8.2 Financial performance
15.3.8.3 Product benchmarking
15.3.8.4 SWOT analysis
15.3.8.5 Operational capacity
15.3.8.6 Strategic initiatives
15.3.9 Advanced BioScience Laboratories, Inc. (ABL, Inc.)
15.3.9.1 Company overview
15.3.9.2 Financial performance
15.3.9.3 Product benchmarking
15.3.9.4 SWOT analysis
15.3.9.5 Operational capacity
15.3.9.6 Strategic initiatives
15.3.10 Novasep Holding S.A.S
15.3.10.1 Company overview
15.3.10.2 Product benchmarking
15.3.10.3 SWOT analysis
15.3.10.4 Operational capacity
15.3.10.5 Strategic initiatives
15.3.11 ATVIO Biotech Ltd
15.3.11.1 Company overview
15.3.11.2 Financial performance
15.3.11.3 Product benchmarking
15.3.11.4 SWOT analysis
15.3.11.5 Operational capacity
15.3.11.6 Strategic initiatives
15.3.12 Vigene Biosciences, Inc.
15.3.12.1 Company overview
15.3.12.2 Financial performance
15.3.12.3 Product benchmarking
15.3.12.4 SWOT analysis
15.3.12.5 Operational capacity
15.3.12.6 Strategic initiatives
15.3.13 General Electric Company (GE Healthcare)
15.3.13.1 Company overview
15.3.13.2 Financial performance
15.3.13.3 Product benchmarking
15.3.13.4 SWOT analysis
15.3.13.5 Operational capacity
15.3.13.6 Strategic initiatives
15.3.14 CEVEC Pharmaceuticals GmbH
15.3.14.1 Company overview
15.3.14.2 Financial performance
15.3.14.3 Product benchmarking
15.3.14.4 SWOT analysis
15.3.14.5 Operational capacity
15.3.14.6 Strategic initiatives
15.3.15 Batavia Biosciences B.V.
15.3.15.1 Company overview
15.3.15.2 Financial performance
15.3.15.3 Product benchmarking
15.3.15.4 SWOT analysis
15.3.15.5 Operational capacity
15.3.15.6 Strategic initiatives
15.3.16 Biovian Oy
15.3.16.1 Company overview
15.3.16.2 Financial performance
15.3.16.3 Product benchmarking
15.3.16.4 SWOT analysis
15.3.16.5 Operational capacity
15.3.16.6 Strategic initiatives
15.3.17 Wuxi AppTec Co., Ltd.
15.3.17.1 Company overview
15.3.17.2 Financial performance
15.3.17.3 Product benchmarking
15.3.17.4 SWOT analysis
15.3.17.5 Operational capacity
15.3.17.6 Strategic initiatives
15.3.18 VGXI, Inc.
15.3.18.1 Company overview
15.3.18.2 Financial performance
15.3.18.3 Product benchmarking
15.3.18.4 SWOT analysis
15.3.18.5 Operational capacity
15.3.18.6 Strategic initiatives
15.3.19 Paragon Bioservices, Inc
15.3.19.1 Company overview
15.3.19.2 Financial performance
15.3.19.3 Product benchmarking
15.3.19.4 SWOT analysis
15.3.19.5 Operational capacity
15.3.19.6 Strategic initiatives
15.3.20 Miltenyi Biotec GmbH
15.3.20.1 Company overview
15.3.20.2 Lentigen Technology, Inc.
15.3.20.3 Financial performance
15.3.20.4 Product benchmarking
15.3.20.5 SWOT analysis
15.3.20.6 Operational capacity
15.3.20.7 Strategic initiatives
15.3.21 SIRION Biotech GmbH
15.3.21.1 Company overview
15.3.21.2 Financial performance
15.3.21.3 Product benchmarking
15.3.21.4 SWOT analysis
15.3.21.5 Operational capacity
15.3.21.6 Strategic initiatives
15.3.22 Virovek Incorporation
15.3.22.1 Company overview
15.3.22.2 Financial performance
15.3.22.3 Product benchmarking
15.3.22.4 SWOT analysis
15.3.22.5 Operational capacity
15.3.22.6 Strategic initiatives
15.3.23 BioNTech IMFS GmbH
15.3.23.1 Company overview
15.3.23.2 Financial performance
15.3.23.3 Product benchmarking
15.3.23.4 SWOT analysis
15.3.23.5 Operational capacity
15.3.24 VIVEbiotech S.L.
15.3.24.1 Company overview
15.3.24.2 Financial performance
15.3.24.3 Product benchmarking
15.3.24.4 SWOT analysis
15.3.24.5 Operational capacity
15.3.24.6 Strategic initiatives
15.3.25 Creative Biogene
15.3.25.1 Company overview
15.3.25.2 Product benchmarking
15.3.25.3 SWOT analysis
15.3.26 Vibalogics GmbH
15.3.26.1 Company overview
15.3.26.2 Product benchmarking
15.3.26.3 SWOT analysis
15.3.26.4 Operational capacity
15.3.26.5 Strategic initiatives
15.4 Company Profiles: In-house Manufacturers
15.4.1 Cell and Gene Therapy Catapult
15.4.1.1 Company overview
15.4.1.2 Product benchmarking
15.4.1.3 SWOT analysis
15.4.1.4 Operational capacity
15.4.1.5 Strategic initiatives
15.4.2 BlueBird Bio
15.4.2.1 Company overview
15.4.2.2 Financial performance
15.4.2.3 Product benchmarking
15.4.2.4 SWOT analysis
15.4.2.5 Operational capacity
15.4.2.6 Strategic initiatives
15.4.3 Addgene, Inc.
15.4.3.1 Company overview
15.4.3.2 Financial performance
15.4.3.3 Product benchmarking
15.4.3.4 SWOT analysis
15.4.3.5 Operational capacity
15.4.3.6 Strategic initiatives
15.4.4 Aldevron, L.L.C.
15.4.4.1 Company overview
15.4.4.2 Financial performance
15.4.4.3 Product benchmarking
15.4.4.4 SWOT analysis
15.4.4.5 Operational capacity
15.4.4.6 Strategic initiatives
15.4.5 Audentes Therapeutics
15.4.5.1 Company overview
15.4.5.2 Financial performance
15.4.5.3 Product benchmarking
15.4.5.4 SWOT analysis
15.4.5.5 Operational capacity
15.4.5.6 Strategic initiatives
15.4.6 BioMarin Pharmaceutical
15.4.6.1 Company overview
15.4.6.2 Financial performance
15.4.6.3 Product benchmarking
15.4.6.4 SWOT analysis
15.4.6.5 Operational capacity
15.4.6.6 Strategic initiatives

List of Tables

TABLE 1 Location Mapping
TABLE 2 Production yields of rAAV vectors using different production systems
TABLE 3 Large-scale production of MLV vectors for clinical applications
TABLE 4 Overview of costs involved in cell therapy development
TABLE 5 Common raw/starting materials for viral vector manufacturing
TABLE 6 Sensitivity of baseline process to failure rates during cell therapy production
TABLE 7 Approved cell therapy products
TABLE 8 Approved gene therapy products
TABLE 9 Clinical trials in cancer gene therapy
TABLE 10 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 11 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 12 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 13 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 14 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 15 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 16 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 17 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 18 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 19 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 20 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 21 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 22 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 23 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 24 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 25 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 26 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 27 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 28 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 29 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 30 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 31 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 32 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 33 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 34 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 35 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 36 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 37 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 38 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 39 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 40 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 41 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 42 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 43 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 44 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 44 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 45 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 46 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 47 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 48 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 49 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 50 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 51 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 52 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 53 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 54 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 55 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 56 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 57 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 58 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 59 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 60 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 61 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 62 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 63 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 64 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 65 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 66 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 67 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 68 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 69 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 70 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 71 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 72 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 73 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 74 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 75 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 76 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 77 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 78 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 79 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 80 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 81 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 82 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 83 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 84 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 85 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 86 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 87 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 88 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 89 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 90 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 91 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 92 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
TABLE 93 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million)
TABLE 94 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 95 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 96 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million)
TABLE 97 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million)
TABLE 98 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million)
TABLE 99 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)


★調査レポート[バイラルベクター及びプラスミドDNA製造の世界市場: ベクター別(レンチウイルス、レトロウイルス)、ワークフロー別、用途別、エンドユーザー別、疾患別] (コード:GVR20MA125)販売に関する免責事項を必ずご確認ください。
★調査レポート[バイラルベクター及びプラスミドDNA製造の世界市場: ベクター別(レンチウイルス、レトロウイルス)、ワークフロー別、用途別、エンドユーザー別、疾患別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆